by administrator | Apr 11, 2017 | Appili Therapeutics, News
View original release here For Immediate Release April 11, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc.(“Appili”), an anti-infective drug development company, announced today that it will be receiving an additional $400,000 from the National Research...
by administrator | Feb 17, 2017 | Appili Therapeutics, News
Clostridium difficile – through clinical trials to be ready for market approval. “Having ACOA recognize the potential of our antibiotic reformulation to become a new weapon against anaerobic infections is outstanding,” said Kevin Sullivan, CEO of Appili...
by administrator | Jan 6, 2017 | Appili Therapeutics, News
See original release January 6, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today that Stephen Nicolle has been appointed to its Board of Directors. A seasoned executive, Mr. Nicolle has led...
by administrator | Dec 22, 2016 | Appili Therapeutics, News
See original release here December 21, 2016 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today it raised $2,151,000 in its over-subscribed private placement financing. Participants in this capital...
by administrator | Jul 26, 2016 | Appili Therapeutics, News
entrevestor.com, written by Peter Moreira Kevin Sullivan had the pride of a guy showing off his new Cadillac. But it wasn’t a car he was displaying, it was the new laboratory that his company had recently moved into. The company is Halifax-based drug discovery outfit...
